Galectin Therapeutics, Inc.GALT was a big mover last session, as the company saw its shares rise nearly 17% on the day. The move came after the company received positive FDA feedback that it would be able to continue operations through the rest of the year. This led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 64% in the past one-month time frame.
The company has seen one positive estimate revision in the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Galectin Therapeutics currently holds a Zacks Rank #2 (Buy).
Galectin Therapeutics Inc. Price
Another top stock in the Medical - Drugs industry is Grifols, S.A. GRFS sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>